Orient Pharma (Taiwan) Performance
| 4166 Stock | TWD 37.00 0.05 0.14% |
On a scale of 0 to 100, Orient Pharma holds a performance score of 11. The company holds a Beta of -2.27, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Orient Pharma are expected to decrease by larger amounts. On the other hand, during market turmoil, Orient Pharma is expected to outperform it. Please check Orient Pharma's mean deviation, downside deviation, standard deviation, as well as the relationship between the semi deviation and coefficient of variation , to make a quick decision on whether Orient Pharma's historical price patterns will revert.
Risk-Adjusted Performance
11 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Orient Pharma Co are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Orient Pharma showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Quick Ratio | 0.50 | |
| Fifty Two Week Low | 15.40 | |
| Fifty Two Week High | 21.05 |
Orient |
Orient Pharma Relative Risk vs. Return Landscape
If you would invest 2,590 in Orient Pharma Co on September 24, 2024 and sell it today you would earn a total of 1,110 from holding Orient Pharma Co or generate 42.86% return on investment over 90 days. Orient Pharma Co is generating 0.6686% of daily returns and assumes 4.6557% volatility on return distribution over the 90 days horizon. Simply put, 41% of stocks are less volatile than Orient, and 87% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Orient Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Orient Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Orient Pharma Co, and traders can use it to determine the average amount a Orient Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1436
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | 4166 | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.66 actual daily | 41 59% of assets are more volatile |
Expected Return
| 0.67 actual daily | 13 87% of assets have higher returns |
Risk-Adjusted Return
| 0.14 actual daily | 11 89% of assets perform better |
Based on monthly moving average Orient Pharma is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Orient Pharma by adding it to a well-diversified portfolio.
Orient Pharma Fundamentals Growth
Orient Stock prices reflect investors' perceptions of the future prospects and financial health of Orient Pharma, and Orient Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Orient Stock performance.
| Return On Equity | -14.97 | |||
| Return On Asset | -8.89 | |||
| Profit Margin | (61.79) % | |||
| Operating Margin | (79.63) % | |||
| Current Valuation | 3.23 B | |||
| Shares Outstanding | 156.01 M | |||
| Price To Book | 2.74 X | |||
| Price To Sales | 10.53 X | |||
| Revenue | 285.29 M | |||
| EBITDA | (166.81 M) | |||
| Cash And Equivalents | 64.58 M | |||
| Cash Per Share | 0.41 X | |||
| Total Debt | 287.34 M | |||
| Debt To Equity | 26.20 % | |||
| Book Value Per Share | 7.03 X | |||
| Cash Flow From Operations | (192.55 M) | |||
| Earnings Per Share | (1.13) X | |||
About Orient Pharma Performance
Evaluating Orient Pharma's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Orient Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Orient Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Orient Pharma Co., Ltd. researches, develops, manufactures, and sells drugs in Taiwan and internationally. Orient Pharma Co., Ltd. is a subsidiary of Orient Europharma Co., Ltd. ORIENT PHARMA operates under Drug Manufacturers - Major classification in Taiwan and is traded on Taiwan OTC Exchange.Things to note about Orient Pharma performance evaluation
Checking the ongoing alerts about Orient Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Orient Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Orient Pharma appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 285.29 M. Net Loss for the year was (176.29 M) with profit before overhead, payroll, taxes, and interest of 5.66 M. | |
| Orient Pharma Co has accumulated about 64.58 M in cash with (192.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41. |
- Analyzing Orient Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Orient Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Orient Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Orient Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Orient Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Orient Pharma's stock. These opinions can provide insight into Orient Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Orient Stock Analysis
When running Orient Pharma's price analysis, check to measure Orient Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orient Pharma is operating at the current time. Most of Orient Pharma's value examination focuses on studying past and present price action to predict the probability of Orient Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orient Pharma's price. Additionally, you may evaluate how the addition of Orient Pharma to your portfolios can decrease your overall portfolio volatility.